Bone Graft
-
Biologics
Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use
Approval underscores Cerapedics’ commitment to investing in evidence that brings scientific rigor to bone grafting for spinal fusion. WESTMINSTER, Colo., Sept.…
Read More » -
Biologics
Biogennix Announces Publication of a Scientific Study on Its Advanced Bone Graft Technology
IRVINE, Calif., June 12, 2024 – OrthoSpineNews – Biogennix, an osteobiologics company specializing in products for bone graft procedures, has…
Read More » -
Biologics
5,000 patients treated with OssDsign Catalyst® in the U.S.
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics…
Read More » -
Biologics
Ventris Medical Receives 510(k) Additional Clearance for Amplify® Standalone Bone Graft Putty
Amplify® – Activated Bone Graft NEWPORT BEACH, Calif., March 13, 2024 /PRNewswire/ — Ventris Medical, a privately held orthobiologics and tissue regeneration…
Read More » -
Regulatory
SurGenTec® Receives FDA Clearance for OsteoFlo® HydroPutty™, a Hydrophilic Synthetic Bone Graft
BOCA RATON, Fla., March 7, 2024–(BUSINESS WIRE)–SurGenTec, a pioneering medical device company specializing in orthopedic and spine technologies, proudly announces…
Read More » -
Biologics
Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion
If approved, the breakthrough product will bring Cerapedics’ P-15 Peptide to lumbar spine fusion with a TLIF indication, making it…
Read More » -
Spine
1,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, May 9, 2023 – OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with…
Read More » -
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Biologics
Induce Biologics Announces Launch of NMP Cancellous Strips
Launch is an extension to the company’s Natural Matrix Protein (NMP) family of products TAMPA, Fla., February 28, 2023 /…
Read More » -
Biologics
Comparing the Cellular Effects of Bone Graft Materials: Nanosurfaces vs. Bioglass
Biogennix, February 22, 2023 – OrthoSpineNews – Featured Article One of the critical functions of a bone graft material is to…
Read More » -
Biologics
Kolosis BIO Announces Strong 2022 Results
Kolosis bone grafts continue to gain widespread adoption, now available in over 370 hospitals and surgical facilities across 46 statesThe…
Read More » -
Biologics
Mechanisms of Action for Biologically Active Bone Graft Materials
Biogennix, November 8, 2022 – OrthoSpineNews – Featured Article Biologically active bone grafts are being increasingly favored by surgeons due to…
Read More » -
Biologics
Types of Synthetic Bone Graft Products: Active vs. Passive Materials
Advanced bone graft materials play an active role in the bone healing process by positively influencing cellular healing. Biogennix, October…
Read More » -
Biologics
Ventris Medical Receives 510(k) Clearance for Amplify® Standalone Bone Graft Putty and Bone Graft Extender
NEWPORT BEACH, Calif., Sept. 14, 2022 /PRNewswire/ — Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the…
Read More » -
Biologics
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More »